Galantamine Hydrobromide Market Report 2026

The galantamine hydrobromide market size has grown strongly in recent years. It will grow from $0.73 billion in 2025 to $0.81 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to aging global population, early approval for alzheimer’s treatment, lack of curative therapies for dementia, expansion of long-term care facilities, increased diagnosis of cognitive disorders.

The galantamine hydrobromide market size is expected to see strong growth in the next few years. It will grow to $1.16 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to rising prevalence of alzheimer’s disease, growing geriatric population, demand for symptom management therapies, expansion of home-based dementia care, ongoing neurodegenerative research. Major trends in the forecast period include continued use in alzheimer’s disease management, growing demand for cognitive enhancement therapies, expansion of extended-release formulations, rising adoption in geriatric care settings, increased focus on neurodegenerative disease treatment.

The rising incidence of Alzheimer's disease is projected to propel the galantamine hydrobromide market's expansion over the forecast period. Alzheimer's disease represents a progressive neurodegenerative condition that triggers memory impairment, cognitive deterioration, and behavioral shifts, frequently resulting in the loss of ability to handle everyday activities. The occurrence of Alzheimer's disease continues to climb because of the growing elderly population, since the likelihood of onset sharply increases with advancing age owing to accumulated brain alterations and genetic vulnerabilities. Galantamine hydrobromide plays a key role in Alzheimer's treatment by elevating acetylcholine levels through inhibition of its degradation, thereby aiding in the mitigation of cognitive decline and enhancement of memory among patients experiencing reduced neurotransmitter activity. For instance, in August 2024, data from the Centers for Disease Control and Prevention - a U.S. federal agency - indicated that the number of individuals with Alzheimer's is anticipated to double from 6.9 million to nearly 14 million by 2060. Thus, the escalating prevalence of Alzheimer's disease is fueling demand for galantamine hydrobromide.

Major companies in the galantamine hydrobromide market are prioritizing the development of advanced therapies, like next-generation acetylcholinesterase inhibitors (AChEIs), to boost efficacy, minimize side effects, and improve patient compliance. Next-generation acetylcholinesterase inhibitors (AChEIs) represent sophisticated medications aimed at enhancing cognitive performance in neurodegenerative conditions through better bioavailability and fewer adverse effects. For example, in July 2024, Alpha Cognition Inc., a biopharmaceutical firm based in Canada, revealed that the U.S. Food and Drug Administration (FDA) had approved ALPHA-1062 (Zunveyl), a prodrug derived from the established acetylcholinesterase inhibitor (AChEI) galantamine, for treating mild to moderate Alzheimer’s disease. ALPHA-1062 distinguishes itself with superior safety and bioavailability relative to conventional galantamine versions. In contrast to typical galantamine, it gets absorbed in the small intestine in an inactive state, avoiding early interaction with acetylcholinesterase (AChE) in the gastrointestinal nervous system. This occurs via the addition of a benzyl ester, which curbs local neuronal overstimulation, cuts down on gastrointestinal side effects, and boosts bioavailability. After liver metabolism, ALPHA-1062 transforms into its active form, supplying galantamine to the brain via the bloodstream.

In April 2024, Essential Pharma Group Limited, a UK-based specialty pharmaceutical company, purchased Reminyl (Galantamine Hydrobromide) oral capsules from Janssen Pharmaceutica NV for an undisclosed sum. This purchase guarantees ongoing availability and patient access to galantamine hydrobromide for treating Alzheimer's disease. Janssen Pharmaceuticals, a Belgium-based pharmaceutical company, develops medicines for neurology, infectious diseases, immunology, oncology, and cardiology.

Major companies operating in the galantamine hydrobromide market are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Ajinomoto Co. Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Jubilant Pharmova Limited, Cohance Lifesciences Limited, Indena S.p.A., ScinoPharm Taiwan Ltd., Estechpharma Co. Ltd.​, Nortec Química S.A., Metrochem API Private Limited, Sanochemia Pharmazeutika AG, Pellets Pharma Limited, Midas Pharma GmbH, Jubilant Generics​, Capital Farma, Wuhan Shiji Pharmaceutical Co. Ltd., Credo Life Sciences Pvt. Ltd.

North America was the largest region in the galantamine hydrobromide market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the galantamine hydrobromide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the galantamine hydrobromide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the galantamine hydrobromide market by increasing the cost of imported active pharmaceutical ingredients and chemical intermediates used in cholinesterase inhibitor production. These impacts have been most pronounced in branded and extended-release segments, particularly in north america and europe where api sourcing is internationally linked. Asia-pacific manufacturers have faced cost pressures due to import dependence. However, tariffs have encouraged regional api synthesis and localized drug formulation, supporting long-term supply resilience.

The galantamine hydrobromide market research report is one of a series of new reports that provides galantamine hydrobromide market statistics, including galantamine hydrobromide industry global market size, regional shares, competitors with a galantamine hydrobromide market share, detailed galantamine hydrobromide market segments, market trends and opportunities, and any further data you may need to thrive in the galantamine hydrobromide industry. This galantamine hydrobromide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Galantamine hydrobromide serves as a medication for managing mild to moderate Alzheimer’s disease and various memory disorders. As an acetylcholinesterase inhibitor, it boosts acetylcholine concentrations in the brain, thereby enhancing nerve signal communication and cognitive abilities. Galantamine hydrobromide aids in delaying cognitive deterioration while improving memory, focus, and general mental performance in individuals with neurodegenerative conditions.

The primary galantamine hydrobromide products consist of tablets, capsules, and oral solutions. A tablet represents a solid dosage form ingested orally, which dissolves within the digestive tract to liberate its active components. It finds use in treating Alzheimer's disease, enhancing cognition, and additional applications among diverse end-users like hospitals, research facilities, homecare environments, and long-term care centers.

The galantamine hydrobromide market consists of sales of extended-release capsules, injectable solutions, transdermal patches, sublingual drops, and powder for compounding. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.